If you have any of the following, make sure to talk about it with your doctor: A history of pancreatitis Severe gastrointestinal diseases You are pregnant or breastfeeding A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia If youre undergoing surgery, you may need to stop taking GLP-1 beforehand
Given its unique pharmacological design, retatrutide influences appetite reduction, delayed gastric emptying, glucose regulation, and increased energy expenditure
Phase 2 trial data showed meaningful body weight reduction and improvements in HbA1c, triglycerides, and waist circumference across treatment groups
Peak weight loss acceleration occurs during the dose-titration phase (weeks 4-20), with clinical trial data showing an average loss of 15-22% of baseline body weight by week 20
It has multiple actions including: potentiation of glucose-mediated insulin secretion mechanisms identified: increased -cell proliferation, resulting in an increase -cell mass (Fusco et al, 2017) stimulation of insulin biosynthesis at the translational level, helping to maintain -cell insulin stores and secretory capacity (Baggio & Drucker, 2007) because the GLP-1 effect is glucose-dependent (there is more insulin release when glucose levels are elevated, but less effect when glucose levels are normal), GLP-1 agonists have a lower risk for producing hypoglycemia compared to sulfonylureas (that chronically stimulate insulin release, independent of glucose concentration) suppression of postprandial glucagon release Evidence indicates that stimulation of pancreatic cells by GLP-1 increases their glucose sensitivity, resulting in less glucagon release at any glucose level (Baggio & Drucker, 2007)
Int J Obes (Lond)
